Real-world effectiveness of a digital treatment for amblyopia

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Amblyopia is a neurodevelopmental condition of vision affecting 2-4% of children. Patching therapy is marred by low adherence; over half of patients carry residual functional deficits into adulthood. Luminopia, a prescription digital treatment that incorporates therapeutic modifications into children’s programming via a head-mounted display, was shown to improve visual acuity in a randomized clinical trial (RCT) for amblyopia and led to FDA-clearance, available by prescription. This multicenter registry study compared real-world outcomes to RCT results. Among 40 registry patients, similar in age and amblyopia characteristics, amblyopic eye best-corrected visual acuity improved 1.7 lines (95% CI: 1.2-2.2) after 12 weeks, equivalent to RCT gains (1.8 lines; p=0.0375). Real-world adherence (73%) exceeded that for patching. No adverse events were reported. These findings demonstrate Luminopia's effectiveness in clinical practice, offering a binocular alternative to traditional treatments with high adherence and meaningful visual improvements. Trial Registration: NCT06429280

Article activity feed